IP Library Granted Patent US 10,457,968
Granted Patent B2
US 10,457,968 · App. 13/061,940 · Granted Oct 29, 2019

Modified type A DNA polymerases

Inventors: William Bourn (Western Cape, ZA); Maryke Appel (Western Cape, ZA); Gavin Rush (Western Cape, ZA); John Foskett (Western Cape, ZA); Paul McEwan (Western Cape, ZA)
Assignee: Kapa Biosystems, Inc.
C12P19/34C12N9/1241C12N9/1252C12N15/1058C12Q1/485C12Y207/07007G01N2333/9126
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,457,968
App. No.
13/061,940
Granted
Oct 29, 2019
Kind
B2
Abstract

The present invention provides improved DNA polymerases, in particular, type A DNA polymerases, that may be better suited for applications in recombinant DNA technologies. Among other things, the present invention provides modified DNA polymerases derived from directed evolution experiments designed to select mutations that confer advantageous phenotypes under conditions used in industrial or research applications.

Claims (9)

1. A modified Taq DNA polymerase that:

(i) has an amino acid sequence that has at least 95% amino acid sequence identity with wild type Taq DNA polymerase set out in SEQ ID NO.:1, but includes a substitution relative to SEQ ID NO: 1 at a position corresponding to position 507 of SEQ ID NO.:1, which substitution is E507K; and

(ii) has polymerase activity in catalyzing DNA template-directed synthesis of a DNA polynucleotide, which activity has increased salt-tolerance relative to the wild type Taq DNA polymerase of SEQ ID NO.:1.

2. The modified Taq DNA polymerase of claim 1 , wherein the polymerase has improved ability relative to that of SEQ ID NO.: 1, when used in a PCR reaction, to amplify DNA fragments of 2 kilobases or more in length.

3. The modified Taq DNA polymerase of claim 1 , wherein the polymerase has increased heparin-binding affinity relative to that of SEQ ID NO.: 1.

4. The modified Taq DNA polymerase of claim 1 , wherein the amino acid percent identity is at least 96%.

5. The modified Taq DNA polymerase of claim 1 , wherein the amino acid percent identity is at least 97%.

6. The modified Taq DNA polymerase of claim 1 , wherein the amino acid percent identity is at least 98%.

7. A modified Taq DNA polymerase having the amino acid sequence of SEQ ID NO.:16 (E7S).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2015
From: KAPA BIOSYSTEMS; KAPABIOSYSTEMS; KAPABIOSYSTEMS ET AL
To: KAPA BIOSYSTEMS, INC.
Reel/Frame 036139/0870 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2011
From: MCEWAN, PAUL; APPEL, MARYKE; RUSH, GAVIN; FOSKETT, JOHN; BOURN, WILLIAM
To: KAPA BIOSYSTEMS
Reel/Frame 025972/0029 →
Continuity (2)
Provisional Application 61110877 · Nov 3, 2008
Related Publication 20110281305A1 · Nov 17, 2011
Cited By (1)
US 12,247,230